Spots Global Cancer Trial Database for TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Official Title: A Multicenter Exploratory Study of Paclitaxel+Cisplatin+TQB2450 Injection Combined With or Without Anlotinib in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Study ID: NCT05013697
Conditions
Study Description
Brief Summary: The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma. Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness and safety
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
AnYang Tumor Hospital, Anyang, Henan, China
The People's Hospital Of AnYang City, Anyang, Henan, China
First Affiliated Hospital of Henan University of Science and Technolog, Luoyang, Henan, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Contact Details
Name: Suxia Luo, Doctor
Affiliation: Henan Cancer Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
